MedTrace Logo

NeuroSeq: A Prospective Trial to Evaluate the Diagnostic Yield of Whole Genome Sequencing (WGS) in Adult Neurology

NCT04170985 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2024-05-01

No results posted yet for this study

Summary

Prospective, multi-site, single-arm study to evaluate the diagnostic yield of cWGS in adults with neurological disorders. A single cohort naive of genetic testing will receive standard of care testing for 180 days followed by cWGS. The cohort will be followed for a total of 365 days following enrollment.

Conditions

  • Neurologic Deficits
  • Neurologic Disorder
  • Neurologic Abnormalities

Interventions

OTHER

clinical Whole Genome Sequencing

Participants will receive cWGS as well as standard of care testing. The clinician/site PI will be blinded to the cWGS results until Day 180.

Sponsors & Collaborators

  • Illumina, Inc.

    lead INDUSTRY

Principal Investigators

  • Ryan J Taft, Ph.D · Illumina, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-18
Primary Completion
2024-01-31
Completion
2024-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04170985 on ClinicalTrials.gov